Welcome to our dedicated page for Leap Therapeutic news (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutic stock.
Cypherpunk Technologies Inc., formerly Leap Therapeutics, reports developments tied to its transition from an oncology biotechnology company into an issuer with a digital asset treasury strategy focused on Zcash and its native coin, ZEC. The company changed its name in 2025, while continuing cancer research and development through a wholly owned subsidiary using the Leap Therapeutics name.
Recurring updates include ZEC treasury acquisitions, financing and capital-structure actions, board and leadership changes, quarterly financial results, and oncology program disclosures. The therapeutic pipeline referenced in company updates includes sirexatamab (DKN-01), a monoclonal antibody targeting DKK1, and FL-501, a monoclonal antibody targeting GDF-15.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.